Biogen Enters New Research Deal in Latest Immunology Push

Biogen Inc. struck a deal with a biotech startup to research immune disorder treatments, part of an expansion of its immunology pipeline and a diversification away from risky neuroscience drugs.

Biogen will pay $50 million upfront to Dayra Therapeutics to collaborate on new approaches to treat autoimmune and inflammatory diseases. Dayra is working on macrocyclic peptides, which are pills that have the potential to be as safe and effective as current immunology drugs — but are significantly more convenient. Existing treatments are infused or injected.

The research is still in its early stages. The companies didn’t disclose their specific disease ...